Affiliation:
1. Department of Psychiatry, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia
Abstract
Background:
Schizophrenia is a chronic mental disorder that affects approximately 1% of
the world’s population. Particularly, negative symptoms are frequently resistant and are the main contributors
to the disability on schizophrenia patients. Folic acid and vitamin B12 supplementation is the
safe and affordable approach, which can significantly improve the outcome on the patients with residual
symptoms.
Objectives:
We aimed to understand the difference of negative subscale of Positive and Negative Syndrome
Scale (PANSS) Score on patients with schizophrenia who receive risperidone with the addition
folic acid and Vitamin B12 and patients who receive only risperidone after 6 weeks.
Methods:
This study is a quasi experimental pre-test and post-test designs that are divided into two
groups, they are group receiving risperidone with the addition of folic acid and vitamin B12 and the
group receiving only risperidone. Diagnosis of schizophrenia according to the International Classification
of Diseases (ICD-10) criteria and negative symptoms assessed by using negative subscale of
PANSS Scores are observed. Statistical analysis is conducted using Statistical Package for the Social
Sciences (SPSS) software.
Results:
There was a significant difference in the mean score of negative-scale PANSS scores at the
end of week 6 between the group receiving folic acid and vitamin B12 supplementation and the group
receiving only risperidone with p = 0.002; p <0.05.
Conclusion:
Folic acid and vitamin B12 Supplementation provide benefits to patients schizophrenia.
Publisher
Bentham Science Publishers Ltd.
Subject
Public Health, Environmental and Occupational Health,Nutrition and Dietetics,Food Science
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献